Autoimmune Response to IGF2 mRNA‐Binding Protein 2 (IMP2/p62) in Breast Cancer

Abstract

The purpose of this study was to understand the autoimmune response and immunogenicity of a tumor-associated antigen IMP2/p62 in breast cancer. Autoantibody responses to IMP2/p62 were evaluated by enzyme-linked immunosorbent assay (ELISA), western blotting and indirect immunofluorescence assay in sera from patients with breast cancer, benign breast tumor and normal human individuals. Immunohistochemistry (IHC) study with breast cancer tissues was also performed to analyze protein expression of IMP2/p62. The results have demonstrated that IMP2/p62 can induce a relatively higher frequency of autoantibody response in breast cancer (14.3%, 7/49) compared to patients with benign breast tumor (5.6%, 2/36) and normal individuals (2.2%, 1/44). The frequency of IMP2/p62 expression in breast cancer tissues was significantly higher than that in normal tissues (P<0.01). The data suggest that autoantibody against IMP2/p62 may be a useful serum biomarker for early stage breast cancer screening and diagnosis.

Tumour‐Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta‐Analysis

“…After excluding 579 non‐English articles and 1318 duplicates, 4441 articles not relevant to the topic and 58 meeting the exclusion criteria were excluded. Ultimately, 84 articles were included . A total of 196 specific tumour‐associated autoantibodies (Table S1) were reported, of which 23 specific tumour‐associated autoantibodies (Table ) had been studied more than once.…”

“…The 84 articles included participants from 27 countries (Table S1). The most studied populations were Chinese and American , followed by French , German and Italian . The earliest study was from 1982, and anti‐p53 antibody was the first tumour‐associated autoantibody to be reported in patients with BC.…”

“…The 84 articles included participants from 27 countries (Table S1). The most studied populations were Chinese [22,24,28,29,32,40,42,43,49,50,60,65,69,[92][93][94][95][96] and American [11,21,23,38,41,53,58,64,67,71,72,75,81,84], followed by French [4,25,48,52,62,73,74], German [37,55,57,59,80] and Italian [20,34,56,68,79]. The earliest study was from 1982, and anti-p53 antibody was the first tumour-associated autoantibody to be reported in patients ...…”

Overexpression of IGF2 mRNA‐Binding Protein 2 (IMP2/p62) as a Feature of Basal‐like Breast Cancer Correlates with Short Survival

“…To the Editor: Recent evidence published in this journal suggested that autoantibodies against IMP2/p62 may be useful serum biomarkers for early-stage breast cancer screening and diagnosis [1]. The study by Liu et al [1] elegantly demonstrated that the frequency of autoantibodies against IMP2 and IMP2 expression itself is significantly increased in breast tumour tissues compared to normal tissues.…”

“…The study by Liu et al [1] elegantly demonstrated that the frequency of autoantibodies against IMP2 and IMP2 expression itself is significantly increased in breast tumour tissues compared to normal tissues. An autoimmune response to IMP2/p62 is also known for other tumours, for example colon carcinoma and hepatocellular carcinoma (HCC) [2,3].…”